De Novo SCN8A Mutation Identified by Whole-Exome Sequencing in a Boy With Neonatal Epileptic Encephalopathy, Multiple Congenital Anomalies, and Movement Disorders

Ulvi Vahe, Margit Nõukas, Tiit Nikopensius, Mart Kals, Tarmo Annilo, Mari Nelis, Katrin Õunap, Tiia Reimand, Inga Talvik, Pilvi Ilves, Andres Piirsoo, Enn Seppet, Andres Metspalu and Tiina Talvik

J Child Neurol published online 18 December 2013
DOI: 10.1177/0883073813511300

The online version of this article can be found at:
http://jcn.sagepub.com/content/early/2013/12/16/0883073813511300

Published by:

SAGE
http://www.sagepublications.com

Additional services and information for Journal of Child Neurology can be found at:

Email Alerts: http://jcn.sagepub.com/cgi/alerts
Subscriptions: http://jcn.sagepub.com/subscriptions
Reprints: http://www.sagepub.com/journalsReprints.nav
Permissions: http://www.sagepub.com/journalsPermissions.nav

>> OnlineFirst Version of Record - Dec 18, 2013
What is This?
De Novo SCN8A Mutation Identified by Whole-Exome Sequencing in a Boy With Neonatal Epileptic Encephalopathy, Multiple Congenital Anomalies, and Movement Disorders

Ulvi Vaher, MD1, Margit Nõukas, MSc2,3, Tiit Nikopensius, PhD2,3, Mart Kals, MSc2, Tarmo Annilo, PhD2,3, Mari Nelis, PhD2, Katrin Õunap, MD, PhD1,4, Tiia Reimand, MD, PhD1,4,5, Inga Talvik, MD, PhD1,6, Pilvi Ilves, MD, PhD7, Andres Piirsoo, PhD5, Enn Seppet, PhD8, Andres Metspalu, MD, PhD2,3, and Tiina Talvik, MD, PhD1,6

Abstract
Epileptic encephalopathies represent a clinically and genetically heterogeneous group of disorders, majority of which are of unknown etiology. We used whole-exome sequencing of a parent-offspring trio to identify the cause of early infantile epileptic encephalopathy in a boy with neonatal seizures, movement disorders, and multiple congenital anomalies who died at the age of 17 months because of respiratory illness and identified a de novo heterozygous missense mutation (c.3979A>G; p.Ile1327Val) in SCN8A (voltage-gated sodium-channel type VIII alpha subunit) gene. The variant was confirmed in the proband with Sanger sequencing. Because the clinical phenotype associated with SCN8A mutations has previously been identified only in a few patients with or without epileptic seizures, these data together with our results suggest that mutations in SCN8A can lead to early infantile epileptic encephalopathy with a broad phenotypic spectrum. Additional investigations will be worthwhile to determine the prevalence and contribution of SCN8A mutations to epileptic encephalopathies.

Keywords
SCN8A, epileptic encephalopathy, exome sequencing

Epileptic encephalopathies refer to a severe condition where epileptic activity itself can contribute to progressive cognitive, behavioral, and motor dysfunction. However, the encephalopathic effect of seizures can occur in association with any form of epilepsy.1 Children with severe early-onset epilepsies are thought to be at more risk and typically carry a poor prognosis.2 Several genes have been associated with early infantile epileptic encephalopathy, but determining the underlying cause can be challenging because of genetic and phenotypic heterogeneity; therefore, the majority of cases remain unexplained.3

Mutations in neuronal sodium channel genes such as SCN1A, SCN2A, SCN3A, and SCN9A have been described in a growing number of epileptic disorders.4-7 Recently, novel missense mutations in SCN8A have been reported in 2 patients with early infantile epileptic encephalopathy, the first case with epileptic encephalopathy presenting at 6 months of age and with seizures, autism, intellectual disability, ataxia, and sudden unexplained death in epilepsy at 15 years of age.8 The second

1 Children’s Clinic, Tartu University Hospital, Tartu, Estonia
2 Estonian Genome Center, University of Tartu, Tartu, Estonia
3 Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
4 Department of Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia
5 Institute of Biomedicine and Translational Medicine, Department of Biomedicine, University of Tartu, Tartu, Estonia
6 Department of Pediatrics, University of Tartu, Tartu, Estonia
7 Radiology Clinic, Tartu University Hospital, Tartu, Estonia
8 Institute of Biomedicine, Department of Pathophysiology, University of Tartu, Tartu, Estonia

Corresponding Author:
Ulvi Vaher, MD, Children’s Clinic, Tartu University Hospital; Lunini 6, 51014 Tartu, Estonia.
Email: ulvi.vaher@klinikum.ee
case was reported in a patient presenting with epileptic encephalopathy beginning at 18 months of age with no further clinical data available.4

SCN8A gene encodes the neuronal sodium channel α-subunit Nav1.6, with high expression levels in the central and peripheral nervous system where it regulates neuronal firing.9 Nav1.6 forms the ion-conduction pore with voltage sensors in 4 internally repeated domains, each containing 6 transmembrane segments.10 Nav1.6 channels are localized at nodes of Ranvier, dendrites, and synapses.9

In this study, we report a novel SCN8A mutation contributing to early infantile epileptic encephalopathy with a broad spectrum of clinical symptoms. Our results propose SCN8A as a compelling candidate gene to be screened in sporadic cases of epileptic encephalopathies with unknown etiology and demonstrate the value of whole-exome sequencing in clinical practice.

Case Summary

The proband was born at term by emergency cesarean section due to fetal hypoxia with a birth weight of 4575 g and Apgar scores 5/5/6. He was the first child of a nonconsanguineous healthy couple and had a 14-year-old half-sister from the mother’s first marriage, who has benign epilepsy with centrotemporal spikes and normal cognitive functioning. Seizures were present immediately after birth, leading to development of epileptic status. He was intubated and therapeutical hypothermia in general anesthesia was applied for 72 hours, but seizures continued despite the treatment. After weaning of general anesthesia, movement disorders like coarse tremor, myoclonias, and voice expression appeared in addition to seizures. All these symptoms were exaggerated by tactile stimuli. Seizures were generalized tonic with apnea and bradycardia or focal tonic with eye squeezing and mouthing in series up to 60 times per day. His seizures were refractory to treatment and intensive care was needed several times. The patient also had central hypotonia alternating with stiffness. He did not have active movements and head control, except slight head turning, and his eye contact was occasional. The course of seizures and movement disorders were waxing and waning. The boy had dysmorphic facial appearance (high frontal hairline, micrognathia, dysmorphic ears, full cheeks), congenital multiple arthrogryposis, hip dysplasia, inguinal hernia, and hydrocele. Kidney stones were diagnosed at the age of 7 months. He died at the age of 1 year and 5 months because of progressive respiratory failure during respiratory illness. Parents refused autopsy.

Magnetic resonance imaging (MRI) at 1.5 Tesla including diffusion-weighted sequences and spectroscopy performed at the ages of 9 days and 1.5 months did not show any abnormalities. However, at the age of 5 months, mild frontotemporal atrophy and thinning of the corpus callosum and at the age of 11 months moderate bilateral frontotemporal atrophy, thinning of the corpus callosum, and mild delay in white matter myelination were described (Figure 1).

Electroencephalography (EEG) showed mild changes with slight low-voltage background activity and occasional interictal epileptiform discharges in bilateral temporal areas during the first months. Burst-suppression-like pattern (low-voltage 12-16 μV periods alternating with higher-voltage 150 μV bilateral irregular spike-wave bursts) in sleep recording was noticed at 11 months of age. Electroneuromyography and visual evoked potentials measured at the age of 5 months did not show any abnormalities. Results of metabolic investigations including levels of organic acids, amino acids, sugars, purines/pyrimidines, acylcarnitines, oligosaccharides, glycosaminoglycans, creatine guanidinoacetate, very long chain fatty acids, homocysteine, uric acid, copper, and ceruloplasmin were in the normal range. In addition, GM1- and GM2-gangliosidosis, sialidosis, galactosialidosis, neuronal ceroid lipofuscinosis-1, and neuronal ceroid lipofuscinosis-2 were excluded by enzymatic analysis. Neurotransmitter, amino acid and piperolic acid analysis of cerebrospinal fluid were normal. At the age of 1 month 3 weeks, transitory hypoglycorrhachia (glucose in cerebrospinal fluid 2.5 mmol/L and glucose serum/cerebrospinal fluid ratio 0.5) was seen, but it normalized by the age of 4 months. Electron microscopy and immunohistochemistry analysis of muscle biopsy showed features of muscle pathology: damaged hyperchromophilic fibers with increase of lipid deposits and lysosomal enzymes, abnormal mitochondria with loss of inner cristae, and inflammation. Investigation of mitochondrial function revealed no damage of adenosine triphosphate synthesis, but impairment of glutamate connected respiratory function was found. However, respiratory...
chain enzymes in cultured skin fibroblasts and frozen muscle showed normal activity. Further studies, including chromosome analysis by HumanCytoSNP-12 array (Illumina Inc, San Diego, CA), mutation analysis of SLC2A1, POLG, AGC1, and mitochondrial DNA sequencing, revealed no abnormalities.

Seizures were refractory to treatment with different anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, levetiracetam, clonazepam, vigabatrin), vitamins (pyridoxine, pyridoxal phosphate, biotin, folic acid, vitamin B12, carnitine), and ketogenic diet. Levo-dopa/carbidopa did not control the movement disorders.

Exome Sequencing

Exome sequencing was performed on genomic DNA of the affected boy and his healthy parents. Exome capture was performed using TruSeq Exome Enrichment Kit according to the manufacturer’s protocol (Illumina). The captured libraries were sequenced on Illumina HiSeq2500 Sequencer. Sequence reads were aligned to the human reference genome (hg19) using Burrows-Wheeler Aligner 0.6.1.11 Single-nucleotide variants and indels were called with SAMtools 0.1.18, Picard tools 1.60, and the Genome Analysis Toolkit 1.6-7 and annotated with custom scripts.12,13 Genotypes were filtered to retain single-nucleotide polymorphisms and indels with Phred-like quality scores of at least 20. We focused on variants altering protein-coding regions and canonical splice-sites and excluded variants with the frequency of >1% present in public databases (including dbSNP135 and the 1000 Genomes Project) and our in-house exome and full-genome database. Mutation analysis was performed by Sanger sequencing in the proband, his parents, and half-sister.

Results

The average read depth for sequenced exome was 43×. After variant prioritization, we identified a novel heterozygous missense SCN8A mutation c.3979A>G in exon 22 of SCN8A (NM_014191.3), predicting a p.Ile1327Val substitution. In silico analysis using PolyPhen-2, SIFT, PhyloP, and Condel suggested that the mutation has a deleterious effect on protein function. Also, the affected amino acid is located at the extremely conserved position at the cytosolic interface of S4-S5 linker and transmembrane segment 5 in domain 3 (Figure 2A, B). Additional evaluation of dbSNP, NHLBI-ESP Exome Variant server, and other available databases did not reveal the c.3979A>G mutation in SCN8A. This variant was also absent from our local data set of 69 exomes and 86 full genomes previously sequenced in our unit. The variant c.3979A>G was confirmed as a de novo in the proband with Sanger sequencing (Figure 2C).

Discussion

In this study, we describe a single nucleotide substitution in SCN8A that changes the isoleucine at position 1327 to a valine in a patient who had early infantile epileptic encephalopathy...
with variable clinical symptoms. The identified heterozygous missense mutation c.3979A>G is located at the extremely conserved position at the cytosolic interface of S4-S5 linker and transmembrane segment 5 in domain 3 of the Nav1.6 sodium channel (Figure 2A, 2B).14,15

To date, this is the fourth report of a human SCN8A mutation (Figure 2A). In 2 of the previous cases, novel SCN8A mutations have been associated with the pathogenesis of early infantile epileptic encephalopathy, and in 1 case with mental retardation, ataxia and panencephalare atrophy.4,8,16 The significant differences in clinical symptoms suggest that the clinical manifestation of SCN8A mutations might depend on the localization of amino acid substitution in the Nav1.6 sodium channel and the nature of the mutation. The first reported de novo pathogenic missense mutation (c.5302A>G) in epileptic encephalopathy was described in a girl with the onset of seizures at 6 months of age, who also manifested autism, intellectual disability, ataxia, and sudden unexplained death in epilepsy at the age of 15 years. The altered amino acid residue was located at the cytoplasmic end of transmembrane segment 6 in domain 4. Veeramah et al8 performed detailed functional analysis of the p.Asn1768Asp mutant of SCN8A, which showed incomplete channel inactivation and a large increase in persistent sodium current. Based on functional studies performed by Veeramah et al and the phenotype of our patient, we suggest that the p.Ile1327Val mutation could also represent a dominant gain-of-function variant.8 The second identified SCN8A missense mutation in a patient with early infantile epileptic encephalopathy (encoding p.Leu1331Val) was located at the cytosolic end of transmembrane segment 5 in a domain 3. The patient had epileptic encephalopathy beginning at 18 months with no further clinical data available.9 In a patient with mental retardation, ataxia, and panencephalare atrophy, but without seizures, a truncating mutation p.P1719fsX1724 in SCN8A was found.16 Comparing the clinical manifestations, it is important to stress that symptoms in our patient started with fetal hypoxia and very-early-onset refractory seizures. Also, despite frequent and refractory seizures, EEG changes were mild until 11 months of age, when burst-suppression-like pattern developed. Brain atrophy on MRI was first seen at the age of 5 months with progression on later images. Global developmental delay and movement disorders were present in our case since birth, whereas in previous cases it followed epilepsy. Besides the involvement of the nervous system, multiple congenital anomalies were present and other organ systems were affected in our patient. Neither multiple-organ involvement nor neonatal beginning of the disease has been described previously.

Finding the cause of severe and sporadic early infantile epileptic encephalopathy with unknown genetic etiology using traditional clinical practice guidelines represents a considerable challenge. However, we identified a novel pathogenic c.3979A>G missense mutation in SCN8A using whole-exome sequencing approach, demonstrating the value of next-generation sequencing in disease gene discovery as compared to single-gene testing. In conclusion, this study implicates SCN8A in the pathogenesis of epileptic encephalopathy with neonatal beginning. In neonates with perinatal asphyxia and early-onset refractory seizures without signs of hypoxic-ischemic brain injury on neuroimaging, epileptic encephalopathy should be considered. Further investigations will be worthwhile to determine the prevalence and significance of SCN8A mutations in epileptic encephalopathies.

Acknowledgments
We wish to thank the family members for participating in this study. We would like to express our appreciation to Prof. Helen Cross from University College London Institute of Child Health for her valuable suggestions during the treatment of the patient. Also, we would like to thank Lili Milani from Genotyping and Sequencing Core Facility of Estonian Genome Center of Tartu University for her technical assistance in exome sequencing.

Author Contributions
First authors UV and MN have contributed equally to this study. Patient referral and patient’s clinical information was provided by UV, TR, KÖ, IT, and TT; patient’s magnetic resonance image (MRI) was reviewed by PI; muscle tissue investigations were performed by AP and ES; sequencing was carried out and interpreted by MN, TN, MN, MK, TA, and AM; manuscript was written by UV and MN, cowritten and critically revised by TT; all authors contributed to and approved the final version of the paper.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Targeted Financing from the Estonian Ministry of Education and Research (grants SF0180142s08, TARLA 2695); the EuroEPINOMICS (grant SARLA 11091E); the Development Fund of the University of Tartu (grant SP1GVARENG); and the European Regional Development Fund to the Centre of Excellence in Genomics (EXCEGEN; grant 3.2.0304.11-0312).

Ethical Approval
Research Ethics Committee of the University of Tartu approved this study (210/M-5 from December 19, 2011). Written patient consent was obtained from the patient’s parents.

References


